News 26.02.2020 Zurich-Schlieren, Switzerland, February 26, 2020. Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix, its blood-based test for prostate cancer diagnosis, has now been made commercially available in Europe. Proclarix combines proprietary biomarkers and a risk score that accurately identifies an individual patient’s risk for clinically significant prostate cancer. The...
Internal events
Event date: 19.03.2020
Biologics Networking & Knowledge Exchange powered by Lonza
19 March, 2020 at 15:30 followed by an apero
Bio-Technopark Auditorium, Wagistrasse 25, 8952 Schlieren, Switzerland
How do you ensure that your first milestone into the clinic is not your last? Join us to get a head start to IND without jeopardising your drug's future.
Advancing an...
News 20.02.2020 Zurich-Schlieren, Switzerland, February 20, 2020. Molecular Partners AG (SIX: MOLN), a clinicalstage biotech company that is developing a new class of drugs known as DARPin® therapies, today announced the nomination of three new board members, proposed for election at the 2020 Annual General Meeting on April 29, 2020. Nominees are as follows: • Sandip...
Internal events
Event date: 20.02.2020
In this event, representatives from Johnson & Johnson will provide an overview of goals and missions, highlighting how Johnson & Johnson Innovation interacts with the entrepreneurial community through their network of healthcare incubators JLABS, the Venture Fund JJDC, the Innovation Centers and Janssen Business & Development.
Time: 20th February, 17:00 –...
News 06.02.2020 Research & Development: Abicipar in Neovascular Wet Age-Related Macular Degeneration: Two-year results from CEDAR and SEQUOIA presented at AAO in October 2019 demonstrate that vision gains observed after one year with both, every 8-week and every 12-week dosing were maintained in second year FDA and EMA filings accepted and under...